Clascoterone for acne: topical antiandrogen evidence

Clascoterone 1% cream is an FDA-approved topical androgen receptor inhibitor for acne in people 12 years and older [1][2]. In two phase 3 trials, it improved inflammatory and noninflammatory lesion counts and produced higher treatment-success rates than vehicle after 12 weeks [3]. It offers a mechanism that is different from topical retinoids or benzoyl peroxide, but the absolute response rates were modest and the trials did not compare it directly with oral spironolactone.

The useful question is not whether clascoterone “balances hormones” in general. It acts locally at androgen receptors in skin, and its evidence comes from a specific cream, concentration, schedule, and trial population. That evidence cannot be transferred automatically to compounded antiandrogen creams or dietary supplements.

How does clascoterone work?

Androgen signaling can contribute to sebum production and acne biology. Clascoterone competes with androgens at the receptor level in skin [1][2]. The FDA describes it as an androgen receptor inhibitor, not a systemic hormone treatment.

That distinction does not mean systemic exposure is impossible. The prescribing information discusses hypothalamic-pituitary-adrenal axis suppression under maximal-use conditions and elevated potassium observed in some trial participants [1]. These label findings do not establish that common acne use routinely causes either problem, but they prevent a “skin only, therefore risk free” interpretation.

Clascoterone also does not replace every part of acne treatment. Comedones, inflammation, bacterial ecology, scarring risk, pregnancy potential, and tolerance can lead to different combinations. Our topical retinoid review explains the evidence for another major topical mechanism.

What did the phase 3 trials find?

Two identically designed randomized, double-blind trials enrolled 1,440 participants with moderate or severe facial acne. Participants applied clascoterone 1% cream or vehicle twice daily for 12 weeks [3]. The trials included males and nonpregnant females aged 9 years and older, but the FDA indication is for age 12 and older [1][2].

Treatment success required an Investigator's Global Assessment of clear or almost clear plus at least a two-grade improvement [3]. This is a stricter outcome than “some lesions improved.”

Both trials favored clascoterone on the primary treatment-success endpoint and on changes in inflammatory and noninflammatory lesion counts [3]. The absolute rates provide necessary context: around one in five clascoterone recipients met the strict endpoint by week 12. Improvement and complete or near-complete clearing are not the same result.

The trial investigators reported mostly mild local reactions and low adverse-event rates [3]. Cassiopea sponsored the program, company employees were authors, and investigators disclosed compensated advisory roles. Those disclosures do not negate randomization, but they support checking outcomes against the protocol and FDA review rather than relying on promotional summaries.

What did longer follow-up add?

An open-label extension followed participants for up to another nine months. Treatment could be stopped after reaching clear or almost-clear status and resumed if acne worsened [4]. Of 600 participants entering the extension, 343 completed it.

Among 598 participants treated in the extension safety population, 108 (18.1%) experienced a treatment-emergent adverse event [4]. Participants applied treatment to the face and, when selected by the participant or investigator, truncal acne. Facial erythema and scaling or dryness were among the more common local reactions [4]. Among per-protocol completers, the proportion rated clear or almost clear increased over time.

That finding is useful but needs its design attached. There was no continuing randomized vehicle comparison, treatment could stop and restart, and the per-protocol efficacy analysis excludes people who did not complete as planned. A completer percentage should not be presented as the expected result for every person starting treatment.

A systematic review pooled five placebo-controlled trials and found higher Investigator's Global Assessment success with clascoterone, along with a clearer reduction in noninflammatory than inflammatory lesion counts in that analysis [5]. The review was based largely on the same development program rather than many independent, long-term comparative trials.

How does it compare with other hormonal acne options?

Clascoterone is sometimes discussed alongside oral spironolactone because both involve androgen pathways. The comparison has a major evidence gap: the pivotal clascoterone studies used vehicle, not oral spironolactone, as the control [3]. A network comparison or separate trial result cannot show equivalence as reliably as a direct randomized trial.

The products also differ in route, eligible population, contraindications, monitoring considerations, and evidence base. Clascoterone is labeled for acne in males and females aged 12 years and older [1]. Oral spironolactone is used off label for acne, primarily in selected women. Neither statement determines the right choice for an individual.

For adult women with a hormonal pattern, our adult female acne guide reviews the broader diagnostic and treatment context.

Adverse effects and practical limits

The FDA label lists local irritation, including redness, itching, scaling, dryness, stinging, and burning [1]. It also addresses HPA-axis suppression and elevated potassium observed during the development program. Pediatric patients may be more susceptible to systemic toxicity under high exposure [1].

The cream should not be assumed safe for the eyes, mouth, mucous membranes, or untested delivery methods. More product, occlusion, a larger area, or damaged skin can alter exposure. Pregnancy and lactation data are limited in the label [1].

Other evidence limits include:

• The pivotal comparison lasted 12 weeks.
• Industry sponsorship was central to the phase 3 and extension program.
• There was no direct comparison with oral spironolactone, a topical retinoid, benzoyl peroxide, or a full combination regimen.
• The strict endpoint was reached by a minority of treated participants at week 12.
• Trial efficacy cannot show that acne with a different diagnosis, such as rosacea or folliculitis, will respond.

Bottom line

Clascoterone cream is a distinct, FDA-approved topical antiandrogen for acne in people aged 12 years and older [1][2]. Two phase 3 trials showed statistically and clinically greater improvement than vehicle, while absolute treatment-success rates were 18.4% and 20.3% at week 12 [3].

It expands the available mechanisms for acne treatment. It does not establish superiority to oral spironolactone, replace diagnostic assessment, or remove the need to consider local irritation and label safety findings.

This article is for informational purposes and does not constitute medical advice. Acne treatment should be selected with a qualified clinician.